Unknown

Dataset Information

0

The impact of standard accelerated stability conditions on antibody higher order structure as assessed by mass spectrometry.


ABSTRACT: Protein therapeutic higher order structure (HOS) is a quality attribute that can be assessed to help predict shelf life. To model product shelf-life values, possible sample-dependent pathways of degradation that may affect drug efficacy or safety need to be evaluated. As changes in drug thermal stability over time can be correlated with an increased risk of HOS perturbations, the effect of long-term storage on the product should be measured as a function of temperature. Here, complementary high-resolution mass spectrometry methods for HOS analysis were used to identify storage-dependent changes of biotherapeutics (bevacizumab (Avastin), trastuzumab (Herceptin), rituximab (Rituxan), and the NIST reference material 8671 (NISTmAb)) under accelerated or manufacturer-recommended storage conditions. Collision-induced unfolding ion mobility-mass spectrometry data showed changes in monoclonal antibody folded stability profiles that were consistent with the appearance of a characteristic unfolded population. Orthogonal hydrogen-deuterium exchange-mass spectrometry data revealed that the observed changes in unfolding occurred in parallel to changes in HOS localized to the periphery of the hinge region. Using intact reverse-phase liquid chromatography-mass spectrometry, we identified several mass species indicative of peptide backbone hydrolysis, located between the variable and constant domains of the heavy chain of bevacizumab. Taken together, our data highlighted the capability of these approaches to identify age- or temperature-dependent changes in biotherapeutic HOS.

SUBMITTER: Kerr RA 

PROVIDER: S-EPMC6601562 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

The impact of standard accelerated stability conditions on antibody higher order structure as assessed by mass spectrometry.

Kerr Richard A RA   Keire David A DA   Ye Hongping H  

mAbs 20190415 5


Protein therapeutic higher order structure (HOS) is a quality attribute that can be assessed to help predict shelf life. To model product shelf-life values, possible sample-dependent pathways of degradation that may affect drug efficacy or safety need to be evaluated. As changes in drug thermal stability over time can be correlated with an increased risk of HOS perturbations, the effect of long-term storage on the product should be measured as a function of temperature. Here, complementary high-  ...[more]

Similar Datasets

| S-EPMC6512938 | biostudies-literature
| S-EPMC7531764 | biostudies-literature
| S-EPMC8785098 | biostudies-literature
2018-10-04 | GSE112623 | GEO
| S-EPMC7162711 | biostudies-literature
| S-EPMC5975933 | biostudies-literature
| S-EPMC10476649 | biostudies-literature
| S-EPMC10483880 | biostudies-literature
| S-EPMC10017227 | biostudies-literature
| S-EPMC8587657 | biostudies-literature